who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

How Johnson & Johnson (JNJ) makes money: Q3 2026 revenue breakdown

US GAAP, Q3 2026 · quarter ended 09/27/2026 · released Oct 13

Net earnings

$210M

down 95.9% y/y

Sales to customers

$25,399M

up 5.9% y/y

Operating Income (calculated)

$5,845M

down 16.9% y/y

Next report

~ Jan 20

not announced yet

The quarter in brief

Sales rose 5.9% y⁠/⁠y to $25.4B, but net earnings fell 95.9% to $210M ($0.09 per diluted share vs $2.12).

Key growth driver: Innovative Medicine — the fastest-growing revenue line: $16,757, +8% y/y. · by the Q3 2026 report

How does Johnson & Johnson make money?

Johnson & Johnson brought in $25.4 billion of revenue in Q3 2026, up 5.9% year over year. The largest source was Innovative Medicine: $16.8 billion, or 66% of the total, followed by MedTech ($8.64B, 34%). Net income for the quarter was $210 million, down 95.9% year over year.

Revenue by source, Q3 2026
  • Innovative Medicine$16.8B · 66% · +7.7%
  • MedTech$8.64B · 34% · +2.5%

Shares of $25.4B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.

All figures in $M.

Sankey diagram of JNJ (Johnson & Johnson) earnings report for Q3 2026: revenue, costs and profitInnovative Medicine$16,757 · +7.7%MedTech$8,642 · +2.5%Sales tocustomers$25,399 · +5.9%Cost of productssold$8,097 · +10.9%Gross Profit$17,302 · +3.7%68.1% marginSelling,marketing andadministrativeexpenses$6,285 · +6.1%Research anddevelopmentexpense$4,652 · +26.7%In-processresearch anddevelopmentimpairments$339 · vs $0Restructuring$181 · +187%Operating Income(calculated)$5,845 · −16.9%23.0% marginInterest (income)expense, net$31 · +72.2%Other (income)expense, net$5,780 · vs $478Earnings beforeprovision fortaxes on income$34 · −99.5%Income Tax Benefit$176Net earnings$210 · −95.9%$0.09/sh · 0.8% margin
Sankey diagram of JNJ (Johnson & Johnson) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Innovative Medicine$16,757 · +7.7%
MedTech$8,642 · +2.5%
Sales to customers$25,399 · +5.9%
Cost of products sold$8,097 · +10.9%
Gross Profit$17,302 · +3.7% · 68.1% margin
Selling, marketing and administrative expenses$6,285 · +6.1%
Research and development expense$4,652 · +26.7%
In-process research and development impairments$339 · vs $0
Restructuring$181 · +187%
Operating Income (calculated)$5,845 · −16.9% · 23.0% margin
Interest (income) expense, net$31 · +72.2%
Other (income) expense, net$5,780 · vs $478
Earnings before provision for taxes on income$34 · −99.5%
Income Tax Benefit$176
Net earnings$210 · −95.9% · $0.09/sh · 0.8% margin

Verdict: Sales rose 5.9% y/y to $25.4B, but net earnings fell 95.9% to $210M ($0.09 per diluted share vs $2.12).

The new supply chain restructuring program is expected to cost $650–750M through fiscal 2029.

Source and notation

Source: Johnson & Johnson press release, 8-K EX-99.1/99.2 of 10/13/2026 (SEC EDGAR). Operating income is calculated (gross profit minus SG&A, R&D, IPR&D impairments and restructuring) — the release does not print it; segment sales — from the release's segment table.

Open as an image: Johnson & Johnson (JNJ), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Johnson & Johnson (JNJ) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/jnj. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/jnj"><img src="https://whoreportstoday.com/t/jnj/img/johnson-and-johnson-jnj-earnings-sankey.png" alt="Johnson &amp; Johnson (JNJ) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/jnj">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/jnj/img/johnson-and-johnson-jnj-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/jnj">Johnson &amp; Johnson (JNJ) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. · Text: Wikipedia, CC BY-SA 4.0, abridged

The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global. Market share (US pharma & biotech): ≈13% by TTM revenue.

Heads-up

Company reports

Q3 2026latest breakdownSales rose 5.9% y/y to $25.4B, but net earnings fell 95.9% to $210M ($0.09 per diluted share vs $2.12).
Q2 2026A solid quarter with reported sales up 6.6% to $25.3B led by Innovative Medicine's 7.8% growth (DARZALEX, CARVYKTI…

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026revenue $101–101.4B (raised)EPS (non-GAAP) $11.05–11.15 (raised)revenue $94.2BEPS (GAAP) $11.03revenue +7…8%

Same quarter a year ago (ended December 28, 2025): revenue $24.56B, EPS (GAAP) $2.08

How we calculate

Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +7%).

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Oct 13, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

JNJ earnings history: past report dates

Oct 13, 2026 Tue8:12 ambefore market openSep 27, 2026$25.4B+6% y/y$0.09−96% y/y
Jul 15, 2026 Wed7:49 ambefore market openJun 28, 2026$25.3B+7% y/y$2.27−1% y/y
Apr 14, 2026 Tue7:35 ambefore market openMar 29, 2026$24.1B+10% y/y$2.14−53% y/y
Jan 21, 2026 Wed7:46 ambefore market openDec 28, 2025≈$24.6B+9% y/y≈$2.08+48% y/y
Oct 14, 2025 Tue7:22 ambefore market openSep 28, 2025$24.0B+7% y/y$2.12+91% y/y
Jul 16, 2025 Wed8:06 ambefore market openJun 29, 2025$23.7B+6% y/y$2.29+19% y/y
Apr 15, 2025 Tue8:14 ambefore market openMar 30, 2025$21.9B+2% y/y$4.54+239% y/y
Jan 22, 2025 Wed6:35 ambefore market openDec 29, 2024≈$22.5B+5% y/y≈$1.41−16% y/y
Oct 15, 2024 Tue7:37 ambefore market openSep 29, 2024$22.5B+5% y/y$1.11−89% y/y
Jul 17, 2024 Wed8:14 ambefore market openJun 30, 2024$22.4B+4% y/y$1.93−2% y/y
Apr 16, 2024 Tue7:06 ambefore market openMar 31, 2024$21.4B+2% y/y$1.34
Jan 23, 2024 Tue7:45 ambefore market openDec 31, 2023$21.4B+7% y/y$1.67+26% y/y
Oct 17, 2023 Tue7:33 ambefore market openOct 1, 2023$21.4B+7% y/y$10.21+508% y/y
Jul 20, 2023 Thu7:15 ambefore market openJul 2, 2023$21.5B+6% y/y$1.96+9% y/y
Show all 14 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Johnson & Johnson: 15-year financials

202594,193—26,80419,698
202488,821—14,06619,842
202385,159—35,15318,248
202279,990—17,94117,185
202178,740—20,87819,758
202082,584—14,71420,189
201982,059—15,11919,918
201881,581—15,29718,531
201776,450—1,30017,777
201671,890—16,54015,541
201570,074—15,40916,106
201474,33121,59016,32314,996
201371,31216,41213,83113,819
201267,22414,95510,85312,462
201165,03013,7659,67211,405

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Johnson & Johnson: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
2025199,21081,54449,93319,70955,62454,126
2024180,10471,49038,38324,10555,89350,321
2023167,55868,77430,80121,85953,49546,282
2022187,37876,80441,19312,88955,29455,802
2021182,01874,02335,88214,48760,97945,226
2020174,89463,27837,06513,98551,23742,493
2019157,72859,47128,89617,30545,27435,964
2018152,95459,75233,08018,10746,03331,230
2017157,30360,16036,08117,82443,08830,537
2016141,20870,41828,82618,97265,03226,287
2015133,41171,15026,86113,73260,21027,747
2014130,35869,75222,36014,52355,74425,031
2013132,68374,05323,08020,92756,40725,675
2012121,34764,82620,86514,91146,11624,262
2011113,64457,08026,32724,54254,31622,811

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-27 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated18,85017,221+1,629
· incl. D&A (non-cash add-back)depreciation & amortization6,0805,492
· incl. stock-based comp (non-cash)share-based compensation1,1151,045
Capexpurchases of property & equipment−3,732−2,995−737
Free cash flow ≈operating cash flow − capex15,11814,226+892
Investing activities, netcapex, acquisitions, securities−4,859−19,103+14,244
· incl. acquisitionsbusinesses net of cash acquired−352−14,459+14,107
Financing activities, netdebt, buybacks, dividends−16,780−4,170−12,610
· incl. buybacksrepurchases of common stock−5,958−4,029−1,929
· incl. dividends paid−9,585−9,250−335
FX effect on cash−10178−188
Net change in cash−2,799−5,874+3,075
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 27, 2026: $81.5B (41% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Jul 2026Per the Q2 2026 10-Q, the shareholder suit over talc risk disclosure is unresolved: a class has been certified, the Supreme Court denied review in April 2026, and expert discovery is under way. sec.gov ↗
  • Dec 2025Dividend per share: $3.98 (2020), $4.45 (2022), $5.14 (2025) — raised every year (XBRL 10-K). data.sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Feb 2026Per the 2025 10-K, one class of shares; diluted share count −9.0% over 5 years (XBRL). sec.gov ↗

Scoring: 2.0, no deductions = 2.0

Share classes
Single class of common stock (10-K cover).
Dilution
Diluted share count −9.0% over 5 years (including the 2023 Kenvue exchange offer at a 7% discount in participants' favor); SBC 1.4%.
Disclosure
10-Ks and 10-Qs filed on time, audited US GAAP financials; no deduction.
Dividends
Dividend raised for 60+ consecutive years: $3.98 (2020) → $5.14 (2025).
Lawsuits & regulators
2018 shareholder class action over concealment of asbestos in talc: class certified, Supreme Court denied review (April 2026), now in the expert stage — unresolved, no deduction under the methodology; talc and opioid suits are product-related.
Related parties
No non-arm's-length related-party transactions; the Kenvue exit was done via an exchange offer at a discount in shareholders' favor.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Johnson & Johnson (JNJ) earnings: FAQ

How does Johnson & Johnson make money?

Johnson & Johnson brought in $25.4 billion of revenue in Q3 2026, up 5.9% year over year. The largest source was Innovative Medicine: $16.8 billion, or 66% of the total, followed by MedTech ($8.64B, 34%). Net income for the quarter was $210 million, down 95.9% year over year.

When is JNJ's next earnings date?

We have not yet seen an announcement of the date from Johnson & Johnson (JNJ). Based on last year's report on Jan 21, 2026, the next report is expected around Jan 20, 2027.

What time does JNJ report earnings?

Johnson & Johnson usually reports before market open: its latest results release was filed with the SEC at 8:12 am ET on Oct 13, 2026.

When did JNJ last report earnings?

Johnson & Johnson reported Q3 2026 results on Oct 13, 2026.

What has Johnson & Johnson guided for FY2026?

Company guidance for FY2026: revenue $101–101.4B (raised); EPS (non-GAAP) $11.05–11.15 (raised). A year ago (FY2025): revenue $94.2B, EPS (GAAP) $11.03. Implied growth: revenue +7…8%. Source: the company's earnings release (Form 8-K filed Oct 13, 2026).

Where can I find Johnson & Johnson's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to JNJ's filings; this page breaks the latest report down in a Sankey chart.

What was JNJ's net income in Q3 2026?

Johnson & Johnson reported net income of $210M for Q3 2026 (−95.9% year over year), under US GAAP.

How has Johnson & Johnson's revenue changed since 2011?

Per its 10-K filings, revenue grew 1.4x: $65,030M in 2011 and $94,193M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: LH · Q3 2026 · LLY · Q3 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy